New line to support Accord BioPharma’s UDENYCA®; Expands Bora’s
capacity to serve other partners in oncology and specialty drug manufacturing
BALTIMORE (October 23, 2025) — Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, has installed a new Groninger® FlexPro 50 Isolator Line for Vials & Pre-filled Syringes that will allow it to expand its aseptic fill/finish capabilities for vials and pre-filled syringes.
This expansion of Bora’s Baltimore facility will combine its long-standing CDMO expertise in isolator technology with rigorous compliance standards to manufacture complex therapeutic products with the latest technology and industry knowledge. The new line positions Bora to support key partners, including Accord BioPharma, Inc., with large-scale production of critical therapies.
Bora has partnered with Accord BioPharma to manufacture pre-filled syringes of UDENYCA® (pegfilgrastim-cbqv), a product recently added to Accord’s portfolio. The new isolator line at the Baltimore site will help scale supply of the vital therapy to support immune health in cancer care.
“We’re excited to combine Bora’s manufacturing expertise with Accord’s desire to increase production to meet demand and manufacture in the United States.” said David Fidler, vice president and general manager of Bora Pharmaceuticals Baltimore. “Our team’s deep technical knowledge will play a vital role in accomplishing these goals.”
From early development and scale-up to process optimization and commercial manufacturing, Bora’s experienced teams support customers at every stage of the product lifecycle. The company’s commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora’s role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit boracdmo.com.
###
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com.